In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selected Start-Ups (04/01)

Executive Summary

In Vivo summarizes the technology of several recently founded companies: BioWisdom Ltd. is an Internet R&D portal to support site users through all phases of drug discovery and development. Cardion AG will focus on heart disease treatment and cell transplantation using its platforms in gene therapy and stem cell technology. EngeneOS Inc. platform combines biological and engineered components to create programmable biomolecular machines. FemtoLink Biotechnologies LLC aims to accelerate its clients' discovery efforts with its integrated platform for molecular diagnostics of proteins, metabolites and DNA. Labnetics Inc. will develop low cost, disposable diagnostics using miniaturized sensor beads encased in silicon wafers. SyneCor LLC is an accelerator for new cardiovascular device companies.

You may also be interested in...



Coronavirus Update: Japan's Supercomputer Joins COVID-19 Drug Hunt

Developed by Japan’s national research institute, the supercomputer has been tasked with characterizing the SARS-CoV-2 virus, identifying therapeutic molecules, modeling infection spread and socio-economic impact.

Pipeline Watch: First Approvals For Vadadustat, Daprodustat, In Japan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

MiMedx Raises $150m To Scale Advanced Wound Care Product Biz

Wound care company MiMedx has raised $150m in private equity and debt financing from EW Healthcare Partners and Hayfin Capital Management. The funds will be used to scale commercialization of the company’s amniotic tissue products.

Related Companies

UsernamePublicRestriction

Register

LL1130942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel